Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-788 in Japanese Non-Small Cell Lung Cancer Patients
NCT03807778Phase 1Active, not recruiting
- Sponsor
- Takeda
- Start
- Feb 2019
- Primary completion
- Nov 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of mobocertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Takeda. Primary endpoints: Recommended Phase 2 Dose at 28 days and Objective Response Rate. Started Feb 2019; status: active, not recruiting.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03807778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807778.